Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500103 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL29374445 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL15819852 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL29371100 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL15821533 | 1.00 | DRD2 (0.49) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL24121788 | 0.91 | LMNA (0.46) | — | |
| Maleic Acid SCHEMBL28863175 | 0.87 | DRD2 (0.52) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| Maleic Acid SCHEMBL28863174 | 0.87 | DRD2 (0.52) | DRD2DRD4DRD3KDM4EALDH1A1 | |
| SCHEMBL15818762 | 0.87 | DHFR (0.44) | DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL15818763 | 0.87 | DHFR (0.44) | DRD2DRD4DRD3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114466846-B | Substituted tricyclic compounds as PRMT5 inhibitors and application thereof | 南京圣和药业股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-4352048-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2024-04-17 | — | — | EP | disclosed |
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-112645946-B | Substituted tricyclic compounds as PRMT5 inhibitors and application thereof | 南京圣和药业股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117480162-A | Compounds for the treatment or prophylaxis of PRMT5 mediated diseases | 阿古诺治疗有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-112125886-B | Tricyclic compounds as PRMT5 inhibitors and application thereof | 南京圣和药物研发有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115768764-A | Fused ring compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2022258986-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2022-12-15 | — | — | WO | disclosed |
| CN-115197212-A | Substituted tricyclic compound, preparation method and application thereof | 南京圣和药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115192576-A | Composition containing substituted tricyclic PRMT5 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115197214-A | Preparation method of substituted tricyclic PRMT5 inhibitor | 南京圣和药业股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114466846-A | Substituted tricyclic compound as PRMT5 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-108570059-B | Compound with PRMT5 inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2022-02-08 | — | — | CN | disclosed |